Potentiation of bortezomib-induced apoptosis by TGF-β in cultured human tenon's fibroblasts: Contribution of the PI3K/Akt signaling pathway

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 12, 2010, Pages 6232-6237

  Chung, Eun Jee ^a   Moon, Sang Woong ^b   Jung, Sun Ah ^c   Cho, Young Jae ^c   Kim, Si Wouk ^c   Lee, Joon H ^d  

^a National Health Insurance Corporation   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

^c Department of Environmental Engineering   (United States)

^d Konyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; CELL LEVEL; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FIBROBLAST; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; INCUBATION TIME; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TENON CAPSULE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BORONIC ACIDS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FIBROBLASTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENES, BCL-2; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TENON CAPSULE; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79955944700     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5747     Document Type: Article

References (42)

1. Khaw PT, Chang L, Wong TT, Mead A, Daniels JT, Cordeiro MF. Modulation of wound healing after glaucoma surgery. Curr Opin Ophthalmol. 2001;12(2):143-148.
2. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of antiTGF-β2 antibody as a new postoperative antiscarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44(8):3394-3401.
3. Higginbotham EJ, Stevens RK, Musch DC, et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology. 1996;103(4):650-656.
4. Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol. 1992;110(8):1049-1050.
5. Khaw P, Grehn F, Hollo G, et al. A phase III study of subconjunctival human antitransforming growth factor β(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007;114(10):1822-1830.
6. Cordeiro MF, Reichel MB, Gay JA, D'Esposita F, Alexander RA, Khaw PT. Transforming growth factor-β1, -β2, and -β3 in vivo: effects on normal and mitomycin C-modulated conjunctival scarring. Invest Ophthalmol Vis Sci. 1999;40(9):1975-1982.
7. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors. 1993;8(1):1-9.
8. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factorβ in human aqueous humor. Curr Eye Res. 1990;9(10):963-969.
9. Khaw PT, Occleston NL, Schultz G, Grierson I, Sherwood MB, Larkin G. Activation and suppression of fibroblast function. Eye. 1994;8(pt 2):188 -195.
10. Picht G, Welge-Luessen U, Grehn F, Lutjen-Drecoll E. Transforming growth factor β 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 2001;239(3):199 -207.
11. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-β 2. Exp Eye Res. 1994;59(6):723-727.
12. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101(4):1530-1534.
13. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-3076.
14. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99(22):14374-14379.
15. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med. 2002;8(4 suppl):S49-S54.
16. Sarkozi R, Perco P, Hochegger K, et al. Bortezomib-induced survival signals and genes in human proximal tubular cells. J Pharmacol Exp Ther. 2008;327(3):645-656.
17. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62(17):4996-5000.
18. Zhang T, Yang D, Fan Y, Xie P, Li H. Epigallocatechin-3-gallate enhances ischemia/reperfusion-induced apoptosis in human umbilical vein endothelial cells via AKT and MAPK pathways. Apoptosis. 2009;14(10):1245-1254.
19. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004;110(21):3335-3340.
20. Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation. 2003; 107(17):2250-2256.
21. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther. 2010;9(8):592-603.
22. Han Z, Malik N, Carter T, Reeves WH, Wyche JH, Hendrickson EA. DNA-dependent protein kinase is a target for a CPP32-like apoptotic protease. J Biol Chem. 1996;271(40):25035-25040.
23. Song Q, Lees-Miller SP, Kumar S, et al. DNA-dependent protein kinase catalytic subunit: a target for an ICE-like protease in apoptosis. EMBO J. 1996;15(13):3238-3246.
24. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997;272(20): 12893-12896.
25. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002; 62(4):1083-1086.
26. Cordeiro MF, Chang L, Lim KS, et al. Modulating conjunctival wound healing. Eye (Lond). 2000;14(pt 3B):536-547.
27. Kottler UB, Junemann AG, Aigner T, Zenkel M, Rummelt C, Schlotzer-Schrehardt U. Comparative effects of TGF-β 1 and TGF-β 2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon's capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. Exp Eye Res. 2005;80(1):121-134.
28. Cunliffe IA, Rees RC, Rennie IG. The effect of TGF-β 1 and TGFβ 2 on the proliferation of human Tenon's capsule fibroblasts in tissue culture. Acta Ophthalmol Scand. 1996;74(1):31-35.
29. Jung SA, Lee HK, Yoon JS, et al. Upregulation of TGF-β-induced tissue transglutaminase expression by PI3K-Akt pathway activation in human subconjunctival fibroblasts. Invest Ophthalmol Vis Sci. 2007;48(5):1952-1958.
30. Horowitz JC, Lee DY, Waghray M, et al. Activation of the prosurvival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-β1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem. 2004;279(2):1359-1367.
31. Horowitz JC, Rogers DS, Sharma V, et al. Combinatorial activation of FAK and AKT by transforming growth factor-β1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal. 2007; 19(4):761-771.
32. Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ, Horowitz JC. Endothelin-1 and transforming growth factorβ1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol. 2009;41(4):484-493.
33. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A. 2000;97(8):3850-3855.
34. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem. 2006;281(17):11923-11932.
35. Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene. 2005;24(3):344-354.
36. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. 2003; 9(3):1145-1154.
37. Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther. 2002; 1(10):841-849.
38. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer. 2005;104(9):1794-1807.
39. Lioni M, Noma K, Snyder A, et al. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther. 2008;7(9):2866-2875.
40. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91(3):325-334.
41. Tibbetts RS, Brumbaugh KM, Williams JM, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999;13(2):152-157.
42. Cordeiro MF, Gay JA, Khaw PT. Human antitransforming growthb factor-β2 antibody: a new glaucoma antiscarring agent. Invest Ophthalmol Vis Sci. 1999;40(10):2225-2234.